Synthesis and characterization of gelatin nanoparticles using CDI/NHS as a non-toxic cross-linking system



Gelatin nanoparticles, cross-linked by a mixture of a water soluble carbodiimide (CDI) and N-hydroxysuccinimide (NHS) as a non-toxic cross-linking system, was prepared. The conventional two step desolvation method with acetone as the non-solvent was used. The mean size and size distribution as well as the morphology of the formed nanoparticles were evaluated and compared with those of nanoparticles cross-linked by glutaraldehyde (GA) as the most commonly used cross-linking agent. Furthermore, intrinsic viscosities of the nanoparticles cross-linked by CDI/NHS and GA were measured and compared under various conditions. The results showed the formation of smoother and more homogeneous nanoparticles with smaller size when CDI/NHS used as cross-linking agent under the same synthesis condition. Moreover, nanoparticles encapsulating paracetamol as a model drug were produced by the two different cross-linking agents and were characterized for drug entrapment and loading efficiencies and in vitro drug release. Both drug entrapment and loading efficiencies was higher in the CDI/NHS cross-linked nanoparticles; however, the release kinetics was comparable to that of nanoparticles cross-linked with GA. The differences in the characteristics of CDI/NHS and GA cross-linked nanoparticles were attributed to the different nature of network structures formed by the two cross-linking agents. On the whole, these results suggested that CDI/NHS cross-linked nanoparticles have high potential to be used for drug delivery application in preference to the nanoparticles synthesized by toxic cross-linking agents.


  1. 1.
    Schrieber R, Gareis H. Gelatine handbook. Weinheim: Wiley-VCH; 2007.CrossRefGoogle Scholar
  2. 2.
    Schwick HG, Heide K. Immunochemistry and immunology of collagen and gelatin. Bibl Haematol. 1969;33:111–25.Google Scholar
  3. 3.
    Zwiorek K, Kloeckner J, Wagner E, Coester C. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharmaceut Sci. 2004;7:22–8.Google Scholar
  4. 4.
    Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K. Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes. Biomaterials. 2005;26:2723–32.CrossRefGoogle Scholar
  5. 5.
    Coester CJ, Langer K, von Brisen H, Kreuter J. Gelatin nanoparticles by two-step desolvation—a new preparation method, surface modifications and cell uptake. J Microencapsul. 2000;17:187–93.CrossRefGoogle Scholar
  6. 6.
    Vandervoort J, Ludwig A. Preparation and evaluation of drug-loaded gelatin nanoparticles for topical ophthalmic use. Eur J Pharm Biopharm. 2004;57:251–61.CrossRefGoogle Scholar
  7. 7.
    Saxena A, Sachina K, Bohidar HB, Kamra Verma A. Effect of molecular weight heterogeneity on drug encapsulation efficiency of gelatin nano-particles. Colloids Surf B: Biointerfaces. 2005;45:42–8.CrossRefGoogle Scholar
  8. 8.
    Azarmi Sh, Huang Y, Chen H, McQuarrie S, Abrams D, Roa W, Finlay WH, Miller GG, Löbenberg R. Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. J Pharm Pharmaceut Sci. 2006;9:124–32.Google Scholar
  9. 9.
    Jahanshahi M, Sanati MH, Hajizadeh S, Babaei Z. Gelatin nanoparticle fabrication and optimization of the particle size. Phys Status Solidi (a). 2008;205:2898–902.CrossRefGoogle Scholar
  10. 10.
    Won YW, Kim YH. Preparation and cytotoxicity comparison of type A gelatin nanoparticles with recombinant human gelatin nanoparticles. Macromol Res. 2009;17:464–8.Google Scholar
  11. 11.
    Saraogi GK, Gupta P, Gupta UD, Jain NK, Agrawal GP. Gelatin nanocarriers as potential vectors for effective management of tuberculosis. Int J Pharmaceut. 2010;385:143–9.CrossRefGoogle Scholar
  12. 12.
    Ofokansi K, Winter G, Fricker G, Coester C. Matrix-loaded biodegradable gelatin nanoparticles as new approach to improve drug loading and delivery. Eur J Pharmaceut Biopharmaceut. 2010;76:1–9.CrossRefGoogle Scholar
  13. 13.
    Oppenheim RC, Stewart NF. The manufacture and tumour cell uptake of nanoparticles labelled with fluorescein isothiocyanate. Drug Dev Ind Pharm. 1979;5:563–71.CrossRefGoogle Scholar
  14. 14.
    Leo E, Vandelli MA, Cameroni R, Forni F. Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde: involved of the drug in the cross-linking process. Int J Pharmaceut. 1997;155:75–82.CrossRefGoogle Scholar
  15. 15.
    Leong KW, Mao HQ, Truong VL, Roy K, Walsh SM, August JT. DNA-polycation nanospheres as non-viral gene delivery vehicles. J Control Release. 1998;53:183–93.CrossRefGoogle Scholar
  16. 16.
    Cascone MG, Lazzeri L, Carmignani C, Zhu Z. Gelatin nanoparticles produced by a simple W/O emulsion as delivery system for methotrexate. J Mater Sci Mater Med. 2002;13:523–6.CrossRefGoogle Scholar
  17. 17.
    Bajpai AK, Choubey J. Design of gelatin nanoparticles as swelling controlled delivery system for chloroquine phosphate. J Mater Sci Mater Med. 2006;17:345–58.CrossRefGoogle Scholar
  18. 18.
    Ethirajan A, Schoeller K, Musyanovych A, Ziener U, Landfester K. Synthesis and optimization of gelatin nanoparticles using the miniemulsion process. Biomacromolecules. 2008;9:2383–9.CrossRefGoogle Scholar
  19. 19.
    Kulicke WM, Clasen C. Viscosimetry of polymers and polyelectrolytes. Berlin: Springer; 2004.Google Scholar
  20. 20.
    Vauthier C, Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharmaceut Res. 2009;26:1025–58.CrossRefGoogle Scholar
  21. 21.
    Mohanty B, Bohidar HB. Systematic of alcohol-induced simple coacervation in aqueous gelatin solutions. Biomacromolecules. 2003;4:1080–6.CrossRefGoogle Scholar
  22. 22.
    Olde Damink LHH, Dijkstra PJ, van Luyn MJA, van Wachem PB, Nieuwenhuis P, Feijen J. Glutaraldehyde as crosslinking agent for collagen based biomaterials. J Mater Sci Mater Med. 1995;6:460–72.CrossRefGoogle Scholar
  23. 23.
    Farris S, Song J, Huang Q. Alternative reaction mechanism for the cross-linking of gelatin with glutaraldehyde. J Agric Food Chem. 2010;58:998–1003.CrossRefGoogle Scholar
  24. 24.
    Khor E. Methods for treatment of collagenous tissue for bio-prostheses. Biomaterials. 1997;18:95–105.CrossRefGoogle Scholar
  25. 25.
    Kuijpers AJ, Engbers GHM, Feijen J, De Smedt SC, Meyvis TKL, Demeester J, Krijgsveld J, Zaat SAJ, Dankert J. Characterization of the network structure of carbodiimide cross-linked gelatin gels. Macromolecules. 1999;32:3325–33.CrossRefGoogle Scholar
  26. 26.
    Timkovicz R. Detection of the stable addition of carbodiimide to proteins. Anal Biochem. 1997;79:135–43.CrossRefGoogle Scholar
  27. 27.
    Yamakawa H. Concentration dependence of polymer chain configurations in solution. J Chem Phys. 1961;34:1360–72.CrossRefGoogle Scholar
  28. 28.
    Gupta A, Mohanty B, Bohidar HB. Flory temperature and upper critical solution temperature of gelatin solutions. Biomacromolecules. 2005;6:1623–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.School of Chemistry, University College of ScienceUniversity of TehranTehranIran
  2. 2.Biomaterials Research Center (BRC)University of TehranTehranIran

Personalised recommendations